We are delighted to be collaborating with Reykjavik-based EpiEndo Pharmaceuticals on its First-in-Human Clinical trial of its Lead Compound, EP395, for Chronic Inflammatory Airway Disease.
The trial is led by our Medical Director, Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester.
“I am delighted to say that our single asceding dose study has started and that the first six healthy subjects have been given a dose of EP395,” commented Dr. Ginny Norris, EpiEndo’s Chief Medical Officer. “The study will now continue with further single dosing and, later, multiple dosing. Dosing of our first subjects with EP395 is an important milestone for EpiEndo, as it brings us one step closer to offering a potentially meaningful therapeutic option to patients with COPD. This study will produce important early clinical data to guide our future development plans and continues to demonstrate EpiEndo’s leadership in development of non-antibiotic macrolides.”
Please read more via this press release.